Department of Health and Human Services February 4, 2011 – Federal Register Recent Federal Regulation Documents
Results 1 - 13 of 13
Submission for OMB Review; Comment Request; Pretesting of NIAID's Biomedical HIV Prevention Research Communication Messages
Under the provisions of Section 3507(a)(1)(D) of the Paperwork Reduction Act of 1995, the National Institute of Allergy and Infectious Diseases (NIAID), the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request to review and approve the information collection listed below. This proposed information collection was previously published in the Federal Register on November 17, 2010 (Volume 75, Number 221), page 70270-70271 and allowed 60-days for public comment. In response, NIAID received two requests for copies of the clearance package, which were provided. No additional requests, comments or suggestions were received. The purpose of this notice is to allow an additional 30 days for public comment. The National Institutes of Health may not conduct or sponsor, and the respondent is not required to respond to, an information collection that has been extended, revised, or implemented on or after October 1, 1995, unless it displays a currently valid OMB control number. Proposed Collection: Title: Pretesting of NIAID's Biomedical HIV Prevention Research Communication Messages. Type of Information Collection Request: Revision of a previously approved collection. Need and Use of Information Collection: This is a request for clearance to pretest messages, materials and program activities about biomedical HIV prevention research. The primary objectives of the pretests are to (1) assess audience knowledge, attitudes, behaviors and other characteristics for the planning/development of health messages, education products, communication strategies, and public information programs; and (2) pretest these health messages, products, strategies, and program components while they are in developmental form to assess audience comprehension, reactions, and perceptions. The information obtained from audience research and pretesting results in more effective messages, materials, and programmatic strategies. By maximizing the effectiveness of these messages and strategies for reaching targeted audiences, the frequency with which publications, products, and programs need to be modified is reduced. Frequency of Response: On occasion. Affected Public: Individuals. Type of Respondents: Adults at risk for HIV/AIDS; healthcare providers; representatives of organizations disseminating HIV-related messages or materials. The total reporting burden over the 3-year period is shown in the table below. There are no Capital Costs to report. There are no Operating or Maintenance Costs to report. Note: The burden table below reflects what NIAID anticipates would be accomplished over the total 3-year life of the clearance. (Annual burden, therefore, is one-third of the total figures presented here.)
National Center for Complementary and Alternative Medicine; Announcement of Workshop on Clarifying Directions and Approaches to Mechanistic and Translational Research on Omega-3 Fatty Acids and Their Metabolites
The National Center for Complementary and Alternative Medicine (NCCAM) invites the research community to participate in a Workshop on Clarifying Directions and Approaches to Mechanistic and Translational Research on Omega-3 Fatty Acids and their Metabolites. The purpose of this workshop is to bring together researchers from a variety of fields to discuss cutting edge mechanistic and translational research related to the underlying mechanisms of Omega-3 fatty acids and their metabolites. The goal is to identify opportunities to move Omega-3 fatty acid of research forward by highlighting barriers to progress with potential solutions and elucidation of gaps in the field which can be addressed. The Workshop will take place on February 14-15, 2011. Location: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814. For registration information please contact Dawn Wayman at 301.594.9877 or waymandm@mail.nih.gov. Background: The National Center for Complementary and Alternative Medicine (NCCAM) was established in 1999 with the mission of exploring complementary and alternative healing practices in the context of rigorous science, training CAM researchers, and disseminating authoritative information to the public and professionals. NCCAM funds research grants that explore the science of CAM. For more information, see https://nccam.nih.gov/. Participating: Other institutes participating in this workshop include: the Office of Dietary Supplements (ODS), National Cancer Institute (NCI), National Heart, Blood and Lung Institute (NHLBI), National Institute of Mental Health (NIMH), National Institute on Aging (NIA), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Alcohol Abuse and Alcoholism (NIAAA), and the National Eye Institute (NEI).
Proposed Collection; Comment Request; Short Follow-Up Questionnaire for the National Institutes of Health (NIH)-AARP Diet and Health Study (NCI)
In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the National Cancer Institute (NCI), the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. Proposed Collection: Title: Short Follow-Up Questionnaire for the National Institutes of Health (NIH)-AARP Diet and Health Study (NCI). Type of Information Collection Request: Extension. Need and Use of Information Collection: The purpose of this short 2-page questionnaire is to obtain information on 18 different medical conditions, several medical procedures, and lifestyle characteristics from 485,909 participants of the NIH-AARP Diet and Health Study. The questionnaire will support the ongoing examination between cancer and nutritional exposures. A pilot mailing to 1,600 randomly selected NIH-AARP Diet and Health study participants confirmed the feasibility of the methodology and willingness of respondents to participate in this data collection effort. This questionnaire adheres to The Public Health Service Act, Section 412 (42 U.S.C. 285a-1) and Section 413 (42 U.S.C. 285a-2), which authorizes the Division of Cancer Epidemiology and Genetics of the National Cancer Institute (NCI) to establish and support programs for the detection, diagnosis, prevention and treatment of cancer; and to collect, identify, analyze and disseminate information on cancer research, diagnosis, prevention and treatment. Frequency of Response: Once. Affected Public: Individuals. Type of Respondents: U.S. adults (persons aged 50-85). The annual reporting burden is displayed in the table below. There are no Capital Costs, Operating Costs, and/or Maintenance Costs to report.
Revision to Proposed Collection; Comment Request; The National Children's Study (NCS), Vanguard (Pilot) Study
Under the provisions of Section 3507(a)(1)(D) of the Paperwork Reduction Act of 1995, the National Institute of Child Health and Human Development (NICHD), the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below. This proposed information collection was previously published in the Federal Register on November 15, 2010, pages 69680-69681, and allowed 60 days for public comment. One comment was received. The comment questioned the value and utility of the proposed data collection, stating that this type of research is not needed. The purpose of this notice is to allow an additional 30 days for public comment. The National Institutes of Health may not conduct or sponsor, and the respondent is not required to respond to, an information collection that has been extended, revised, or implemented on or after October 1, 1995, unless it displays a currently valid OMB control number. Proposed Collection: Title: Pilot Study for the National Children's Study Type of Information Collection Request: Revision. Affected entities: Households and individuals. Types of respondents: People potentially affected by this action are pregnant women, women age 18-49 years of age, their husbands or partners, and their children who live in selected areas within National Children's Study sites. Health care professionals, community leaders, and child care personnel are also potentially affected. Frequency of Response: On occasion. See burden table for estimated number of annual responses for each respondent. Need and use of information collection: The purpose of the proposed methodological study is to continue the Vanguard phase of the National Children's Study (NCS) to evaluate the feasibility, acceptability, and cost of recruitment strategies and study design elements for a prospective, national longitudinal study of child health and development. In combination, the sub-studies encompassed by the Vanguard Phase will be used to inform the design of the Main Study of the National Children's Study. We propose to continue data collection among the 37 Vanguard Study locations up to and including the visit planned to take place when the sample children have reached 24 months of age. This would align study visits approved for the initial 7 Vanguard Study locations (which extend past the birth visit to include a 3-, 6-, 9-, 12-, 18- and 24- month visit) with the study visits approved for the 30 additional Vanguard Study locations (which were initially proposed and approved up to and including the birth visit). Extending the data collection of the 30 additional Vanguard Study locations to 24 months of age would support rigorous, empirical evaluation of participant retention as it may relate to recruitment strategy. A strong understanding of how to encourage retention of study participants, particularly during the infancy and early childhood years, will be essential to planning the Main Study. Additionally, continuing data collection post-birth among the alternate recruitment strategy study locations allows us to generate additional data to inform the development of study visit procedures, both for future Vanguard Study efforts and the Main Study. We also propose reintroduction of a limited set of study visit measures to all 37 of the Vanguard Study locations engaged in data collection. Recall that extensive measures, including biospecimens, were previously approved for use in the initial 7 Vanguard Study locations. When the additional 30 locations were added, we streamlined data collection to allow focus on improving recruitment rates. Now that we have the training for those new locations (and retraining for the initial locations) completed, it is an opportune time to reintroduce selected measures that have the benefit of field experience. That field experience has been used to improve their scientific robustness, burden, and cost. These improved measures now require field testing to best inform their suitability for the Main Study. Specifically, we would like to reincorporate a father interview; maternal blood and urine collection; infant cord blood collection; home tap water and dust collection; a pregnancy health care log; and an infant and child health care log. In addition to supporting further testing of refined items, including these measures in the Recruitment Substudy would result in a data collection scope more closely mirroring the anticipated scope of the Main Study, thereby allowing better gauge of data collection scope and resources and the relationship with retention and study logistics over time. We will evaluate the feasibility (technical performance), acceptability (respondent tolerance and impact on study infrastructure), and cost (operations, time, and effort) of each recruitment and retention strategy using pre-determined measures. We will compare these findings and use them as a basis to inform the strategies, or combinations of strategies, that might be used in the Main Study of the NCS. Further details pertaining to the NCS background and planning can be found at: https://www.nationalchildrensstudy.gov. Burden statement: The additional public burden for this study will vary depending on the method of recruitment. The table below provides the annualized average burden per person over the two-year data collection period for all three alternate recruitment strategies. The additional annualized cost to respondents over the two-year data collection period for the 30 locations engaged in the alternate recruitment strategies to extend data collection from birth to age 2 is estimated at $82,000 (based on $10 per hour) and the differential time estimates in Table A.2.e, below. To reintroduce the proposed measures into the 30 locations engaged in the alternate recruitment strategies, the annualized cost to respondents over the same period is estimated at an additional $79,000 (based on $10 per hour) and the differential time estimates in Table A.2.e, below. There are no Capital Costs to report. There are no Operating or Maintenance Costs to report. BILLING CODE 4140-01-P [GRAPHIC] [TIFF OMITTED] TN04FE11.002
Emergency Responder Health Monitoring and Surveillance
The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) announces the availability of the following draft publication for public comment. The document is entitled, ``Emergency Responder Health Monitoring and Surveillance.'' The draft document and instructions for submitting comments can be found at: https://www.cdc.gov/niosh/docket/review/docket223/. The document proposes a new framework for ensuring responder safety and health by monitoring and conducting surveillance of their health and safety during the entire cycle of emergency response, including the pre-deployment, deployment, and post-deployment phases of a response. The proposed system is referred to as the ``Emergency Responder Health Monitoring and Surveillance (ERHMS)'' system, which includes a guidance section describing the principles of ensuring optimal responder safety and health, as well as a tools section to help facilitate the execution of these principles during an actual response. The goals of this proposed system are to ensure that only properly trained and fit responders are deployed to a response, that the health and safety of all responders are appropriately monitored during a response, and that a systematic and comprehensive evaluation be conducted to determine the potential need for long term surveillance of responders' health after their deployment has been completed. This system will help to ensure that hazardous occupational exposures and signs and symptoms observed during an emergency response are utilized to mitigate adverse physical and psychological outcomes and determine whether protective measures are sufficient to prevent or reduce harmful exposures to workers. Data collected during the pre-, during-, and post-deployment phases will also help to identify which responders would benefit from medical referral and possible enrollment in a long- term health surveillance program. The document, entitled ``Emergency Responder Health Monitoring and Surveillance,'' can be viewed at: https://www.cdc.gov/niosh/docket/ review/docket223/. This guidance does not have the force and effect of the law. Public Comment Period: Comments must be received by April 5, 2011.
New Animal Drugs; Masitinib
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect conditional approval of an application for a new animal drug intended for a minor use filed by AB Science. The application for conditional approval provides for the veterinary prescription use of masitinib mesylate tablets in dogs.
Industry Exchange Workshop on Food and Drug Administration Drug and Device Requirements; Public Workshop
The Food and Drug Administration (FDA) Southwest Regional Office, in co-sponsorship with the Association of Food and Drug Officials (AFDO), the Mid-Continental Association of Food and Drug Officials (MCAFDO), and the FDA Medical Device Industry Coalition, is announcing a public workshop entitled ``The Future of Medical Products Regulation: Ensuring Safety and Integrity in a Global Market''. This 2- day public workshop is intended to provide information about FDA drug and device regulation to the regulated industry. Date and Time: The public workshop will be held on June 20 and 21, 2011, from 8 a.m. to 5 p.m. Location: The public workshop will be held at the Marriott Dallas/ Plano at Legacy Town Center, Plano, Texas, 7120 Dallas Pkwy., Plano, Texas 75024, 972-473-6444, or toll-free 888-236-2427. Attendees are responsible for their own accommodations. To make reservations at the Marriott Dallas/Plano at Legacy Town Center, at the reduced conference rate, contact the Marriott Dallas/Plano at Legacy Town Center before May 20, 2011, citing meeting code ``AFDO Conference''. Contact: David Arvelo, Food and Drug Administration, 4040 North Central Expressway, suite 900, Dallas, Texas 75204, 214-253-4952, FAX: 214-253-4970, e-mail: David.Arvelo@fda.hhs.gov. Registration: You are encouraged to register by May 24, 2011. The AFDO registration fees cover the cost of facilities, materials, and breaks. Seats are limited; therefore, please submit your registration as soon as possible. Course space will be filled in order of receipt of registration. Those accepted into the course will receive confirmation. Registration will close after the course is filled. Registration at the site is not guaranteed but may be possible on a space available basis on the day of the public workshop beginning at 7:30 a.m. The cost of registration follows:
Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Animal Drug User Fees and Fee Waivers and Reductions
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.